PDCD1 and non-small cell lung carcinoma: For instance, high tumor PD-L1 expression has been widely explored as a potential predictive biomarker for selecting patients who will derive benefit from anti-PD-1/PD-L1 therapy in primary NSCLC and melanoma, but studies have not specifically focused on BM [98, 99].